Emerald Mutual Fund Advisers Trust Makes New $1.20 Million Investment in Xeris Biopharma Holdings, Inc. $XERS

Emerald Mutual Fund Advisers Trust purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 207,543 shares of the company’s stock, valued at approximately $1,204,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Principal Financial Group Inc. grew its position in shares of Xeris Biopharma by 38.5% during the 1st quarter. Principal Financial Group Inc. now owns 208,507 shares of the company’s stock worth $1,209,000 after buying an additional 57,948 shares during the period. Chicago Partners Investment Group LLC bought a new position in Xeris Biopharma during the first quarter worth $81,000. Hsbc Holdings PLC bought a new position in Xeris Biopharma during the first quarter worth $183,000. R Squared Ltd acquired a new stake in Xeris Biopharma in the first quarter worth $80,000. Finally, Y Intercept Hong Kong Ltd increased its stake in Xeris Biopharma by 78.5% in the first quarter. Y Intercept Hong Kong Ltd now owns 161,793 shares of the company’s stock valued at $938,000 after purchasing an additional 71,148 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.80.

Insider Activity

In other news, Director Dawn Halkuff sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares of the company’s stock, valued at $578,550. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02. Following the completion of the sale, the insider owned 1,176,506 shares in the company, valued at $7,129,626.36. This represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 251,500 shares of company stock valued at $1,846,457. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma Price Performance

Shares of XERS opened at $8.28 on Wednesday. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.87 and a 12-month high of $10.08. The business’s fifty day moving average is $6.94 and its 200 day moving average is $6.69. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The stock has a market cap of $1.43 billion, a P/E ratio of 138.00 and a beta of 0.62.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.